Glucosamine

Verify with FDA CVM →

1,191 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,191
Total Reports
133
Deaths Reported
1120.0%
Death Rate

Active Ingredients

Glucosamine

Administration Routes

OralUnknownSubcutaneousAuricular (Otic)Topical

Species Affected

Dog 1,137
Cat 47
Human 3
Unknown 2
Horse 2

Most Affected Breeds

Retriever - Labrador 235
Retriever - Golden 80
Crossbred Canine/dog 60
Shepherd Dog - German 56
Boxer (German Boxer) 38
Domestic Shorthair 33
Shepherd Dog - Australian 32
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 25
Collie - Border 25
Pit Bull 22

Most Reported Reactions

Vomiting 215
Lethargy (see also Central nervous system depression in 'Neurological') 207
Emesis 155
Diarrhoea 136
Lack of efficacy - NOS 95
Death by euthanasia 85
Seizure NOS 80
Elevated alanine aminotransferase (ALT) 79
Weight loss 71
Decreased appetite 70
Other abnormal test result NOS 70
Anorexia 68

Outcome Breakdown

Recovered/Normal
402 (33.8%)
Ongoing
325 (27.3%)
Outcome Unknown
281 (23.6%)
Euthanized
85 (7.1%)
Recovered with Sequela
48 (4.0%)
Died
48 (4.0%)

Data Summary

Metric Value
Total adverse event reports 1,191
Reports involving death 133
Case-fatality rate (reported events) 1120.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,191 adverse event reports referencing Glucosamine, including 133 reports in which the animal died — a 1120.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine. Reported administration routes include Oral, Unknown, Subcutaneous, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine reports are Dog (1,137 reports), Cat (47 reports), Human (3 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (235), Retriever - Golden (80), Crossbred Canine/dog (60) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine are Vomiting (215), Lethargy (see also Central nervous system depression in 'Neurological') (207), Emesis (155), Diarrhoea (136). Of the 1,189 reports with a coded outcome, Recovered/Normal is the leading category at 33.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial